At New England Retina Consultants, we are committed to providing the highest quality retina care to our patients. To accommodate a growing and important aspect of exceptional retinal care, we have a facility completely dedicated to retinal investigations.

The Retina Research Institute at New England Retina Consultants has a strong commitment to the advancement of treatments for retinal conditions. If you or someone you know is interested in more information about our clinical trial program, please contact our research coordinator, Rachel O’brien, 413-788-6044 or rachel.obrien@neretina.com.

Ongoing Trials

Geographic Atrophy Secondary to Age-related Macular Degeneration

ALXN2040-GA-201 (Alexion Pharmaceuticals, Inc) – A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

GATHER2-ISEE2009 (Iveric Bio) —An Open-Label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy who Previously Completed Phase 3 Study ISEE2008 (GATHER2)

GATHER2-ISEE2008 (Iveric Bio) — A Phase 3 Multicenter, Randomized, Double-Masked, Sham Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration.

ARCHER – ANX007-GA-01 (Annexon Biosciences) – A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

GALE-APL2-GA-305 – A Phase 3, Open-label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Neovascular AMD (wet macular degeneration)

CONQUER – AM712/ASKG712 (Affamed Therapeutics) – A Prospective, Multi-Center, Open-Label, Sequential, Multiple Ascending-Dose and Randomized Dose-Expansion Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration

DAVIO2 – EYP-1901-201 (Eyepoint Pharmaceuticals, Inc) – A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD

SHORE-OPT-302 (Opthea) – A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Diabetic Retinopathy / Diabetic Macular Edema

CU06-1004 (Curacle Co., Ltd.) – A Randomized, Open-label, Parallel-group, Multi-center Phase 2a Study to Evaluate the Efficacy and Safety of CU06- 1004 for 12 Weeks in Patients with Diabetic Macular Edema (DME)

PAIVA – EPY-1901-204 (Eyepoint Pharmaceuticals, Inc) – A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Other Retinal Conditions

HONU – GE43220 (Genentech) – A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration.

Past Trials

The DAVIO Study – EYP-1091 (Eyepoint Pharmaceuticals) — A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects with wet AMD

ZETA-1-OPI-APXDR-201 (Ocuphire Pharma) – Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy or Mild Proliferative Diabetic Retinopathy

ADX-2191-PVR (Aldeyra Therapeutics, Inc) – A Multicenter, Randomized, Controlled, Prospective, Adaptive Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard of Care For The Prevention of Proliferative Vitreoretinopathy

Renexus (Neurotech): A phase III multicenter randomized, sham controlled study to determine the safety and efficacy of Renexus in macular telangiectasia type 2

RECLAIM-2 (Stealth Biotherapeutics)— A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy

DAZZLE (Kodiak Sciences, Inc) – A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration

MACTEL: A natural history observation and registry study of macular telangiectasia type 2; the mactel study

DERBY-APL2-303 (Apellis) -A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

OAKS-APL2-304 (Apellis) – A phase III, multi-center, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

INTEGRAL -THR-687-002 (Oxurion) – A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic macular oedema (DME)

GATHER1-OPH2003 (Ophthotech)- A phase 2/3 randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreous administration of Zimura (Anti-C5 apatmer) in subjects with geographic atrophy secondary to dry age-related macular degeneration

MERLIN (Novartis) – A multi-center, double masked phase 3a study to assess safety and efficacy of brolucizumab 6mg q4 weeks compared to aflibercept 2mg q4 weeks in patients with neovascular age-related macular degeneration with persistent retinal fluid

KESTREL (Novartis) – A Two-Year, Three-Arm, Randomized, Double-Masked,
Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema

PANDA2 (Chengdu Kanghong Biotechnology) – A multi-center, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of Conbercept intravitreal injection in subjects with neovascular age-related macular degeneration

Comparison between retinal images captured by NOTAL-OCT V2.5 and Zeiss
Cirrus/Heidelberg Spectralis SDOCT

TOPAZ (Clearside Biomedical)- A randomized, masked, controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in combination with an intravitreal anti-VEGF agent in subjects with retinal vein occlusion

Comparative Study of Canon OCT-HS100 with OCT Angiography and the RTVue XR OCT with Avanti with AngioVue Software/ORA Study

Apex Study (Tyrogenex) – A randomized, double-masked, placebo-controlled, dose-finding, non-inferiority study of X-82 plus prn ivt anti-VEGF compared to prn ivt anti-VEGF monotherapy in neovascular AMD

Eyetech EOP1004 (Macugen)
Genentech MARINA (Lucentis)
Genentech ANCHOR (Lucentis)
Genentech PIER (Lucentis)
Genentech HORIZON (Lucentis)
Genentech SAILOR (Lucentis)
Allergan Posurdex 206207-001 (Ozurdex)
Allergan Posurdex 206207-009 (Ozurdex)
Regeneron READ 2 (Eylea)
Genentech SEVEN-UP (Lucentis)